$GNPX
Genprex Inc

2021 Q3 Form 10-Q Financial Statement

#000143774921019892 Filed on August 13, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.000M $2.458M $2.220M
YoY Change 40.88% 10.73% -30.63%
% of Gross Profit
Research & Development $1.432M $1.526M $2.156M
YoY Change 6.07% -29.2% 329.38%
% of Gross Profit
Depreciation & Amortization $6.489K $2.848K $5.776K
YoY Change 13.56% -50.69% 85.25%
% of Gross Profit
Operating Expenses $1.432M $1.526M $2.156M
YoY Change 6.07% -29.2% 329.38%
Operating Profit -$3.439M -$3.987M -$4.378M
YoY Change 23.81% -8.93% 18.2%
Interest Expense $1.060K $1.100K $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$3.438M -$3.986M -$4.370M
YoY Change 24.11% -8.78% 18.11%
Income Tax
% Of Pretax Income
Net Earnings -$3.438M -$3.986M -$4.373M
YoY Change 23.89% -8.85% 18.35%
Net Earnings / Revenue
Basic Earnings Per Share -$0.07 -$0.08
Diluted Earnings Per Share -$72.21K -$84.14K -$123.6K
COMMON SHARES
Basic Shares Outstanding 47.53M 47.37M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $42.02M $44.24M $22.13M
YoY Change 99.53% 99.93% 391.78%
Cash & Equivalents $42.02M $44.24M $22.13M
Short-Term Investments
Other Short-Term Assets $749.0K $755.6K $1.140M
YoY Change -22.78% -33.72% 153.33%
Inventory $2.875M $3.062M $890.0K
Prepaid Expenses
Receivables $127.00 $127.00 $0.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $45.64M $48.06M $24.16M
YoY Change 100.98% 98.95% 316.38%
LONG-TERM ASSETS
Property, Plant & Equipment $44.34K $39.49K $46.29K
YoY Change 4.73% -14.68% 89.97%
Goodwill
YoY Change
Intangibles $627.4K $619.7K $534.5K
YoY Change 6.75% 15.93% 26.82%
Long-Term Investments
YoY Change
Other Assets $638.1K $630.4K $545.3K
YoY Change 6.63% 15.62% 24.6%
Total Long-Term Assets $682.4K $669.9K $591.6K
YoY Change 6.5% 13.25% 28.05%
TOTAL ASSETS
Total Short-Term Assets $45.64M $48.06M $24.16M
Total Long-Term Assets $682.4K $669.9K $591.6K
Total Assets $46.33M $48.73M $24.75M
YoY Change 98.39% 96.9% 295.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $591.9K $369.8K $180.0K
YoY Change 84.98% 105.44% -79.55%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.162M $1.047M $239.8K
YoY Change 209.3% 336.73% -74.46%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.162M $1.047M $239.8K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.162M $1.047M $240.0K
YoY Change 205.76% 336.34% -74.47%
SHAREHOLDERS EQUITY
Retained Earnings -$72.34M -$68.90M -$50.42M
YoY Change 35.99% 36.65% 41.31%
Common Stock $47.80K $47.52K $38.63K
YoY Change 21.13% 23.02% 144.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $45.17M $47.68M $24.51M
YoY Change
Total Liabilities & Shareholders Equity $46.33M $48.73M $24.75M
YoY Change 98.39% 96.9% 295.11%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$3.438M -$3.986M -$4.373M
YoY Change 23.89% -8.85% 18.35%
Depreciation, Depletion And Amortization $6.489K $2.848K $5.776K
YoY Change 13.56% -50.69% 85.25%
Cash From Operating Activities -$2.635M -$2.962M -$3.510M
YoY Change 31.08% -15.61% 123.57%
INVESTING ACTIVITIES
Capital Expenditures -$19.03K $72.81K $0.00
YoY Change -61.94% -100.0%
Acquisitions
YoY Change
Other Investing Activities $187.3K -$41.32K -$10.00K
YoY Change -10.8% 313.2% -98.82%
Cash From Investing Activities $168.3K $31.49K -$10.00K
YoY Change 12.19% -414.9% -98.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 243.5K 114.4K 2.570M
YoY Change -69.17% -95.55%
NET CHANGE
Cash From Operating Activities -2.635M -2.962M -3.510M
Cash From Investing Activities 168.3K 31.49K -10.00K
Cash From Financing Activities 243.5K 114.4K 2.570M
Net Change In Cash -2.223M -2.816M -950.0K
YoY Change 107.75% 196.45% -61.38%
FREE CASH FLOW
Cash From Operating Activities -$2.635M -$2.962M -$3.510M
Capital Expenditures -$19.03K $72.81K $0.00
Free Cash Flow -$2.616M -$3.035M -$3.510M
YoY Change 33.46% -13.54% 129.41%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
47527857
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47522857
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47522857
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43117681
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43117681
CY2011 gnpx Proceeds From State Of Texas Emerging Technology Fund Award
ProceedsFromStateOfTexasEmergingTechnologyFundAward
2250000 USD
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44243449 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27319685 USD
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
127 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
127 USD
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
755596 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
384553 USD
CY2021Q2 gnpx Research And Development Assets Current
ResearchAndDevelopmentAssetsCurrent
3062357 USD
CY2020Q4 gnpx Research And Development Assets Current
ResearchAndDevelopmentAssetsCurrent
3011042 USD
CY2021Q2 us-gaap Assets Current
AssetsCurrent
48061529 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
30715407 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
39494 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
39441 USD
CY2021Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
10741 USD
CY2020Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
10741 USD
CY2021Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
619673 USD
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
601625 USD
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
630414 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
612366 USD
CY2021Q2 us-gaap Assets
Assets
48731437 USD
CY2020Q4 us-gaap Assets
Assets
31367214 USD
CY2021Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
369792 USD
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
192968 USD
CY2021Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
677427 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
257756 USD
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1047219 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
450724 USD
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
47523 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
43118 USD
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
116534756 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
89295601 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-68898060 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-58422229 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
47684218 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
30916490 USD
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
48731437 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31367214 USD
CY2021Q2 us-gaap Revenues
Revenues
0 USD
CY2020Q2 us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
0 USD
CY2021Q2 us-gaap Depreciation
Depreciation
2848 USD
CY2020Q2 us-gaap Depreciation
Depreciation
5776 USD
us-gaap Depreciation
Depreciation
9090 USD
us-gaap Depreciation
Depreciation
11129 USD
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1526277 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2155637 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3695420 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3633514 USD
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2458097 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2216691 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6774407 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6309687 USD
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
3987222 USD
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
4378104 USD
us-gaap Costs And Expenses
CostsAndExpenses
10478917 USD
us-gaap Costs And Expenses
CostsAndExpenses
9954330 USD
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3987222 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4378104 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-10478917 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-9954330 USD
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1104 USD
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
4811 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
3086 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
14817 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3986118 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4373293 USD
us-gaap Net Income Loss
NetIncomeLoss
-10475831 USD
us-gaap Net Income Loss
NetIncomeLoss
-9939513 USD
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47372490
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35358058
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
46464343
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31655400
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
3023545 USD
CY2020Q1 gnpx Issuance Of Stock For Cash Equity Impact
IssuanceOfStockForCashEquityImpact
25731640 USD
CY2020Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1550 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
752444 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-5566220 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
23942959 USD
CY2020Q2 gnpx Issuance Of Stock For Cash Equity Impact
IssuanceOfStockForCashEquityImpact
2569226 USD
CY2020Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
11000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2359621 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4373293 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
24509513 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
30916490 USD
CY2021Q1 gnpx Issuance Of Stock For Cash Equity Impact
IssuanceOfStockForCashEquityImpact
25324330 USD
CY2021Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
20650 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
651088 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-6489714 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
50422845 USD
CY2021Q2 gnpx Issuance Of Stock For Cash Equity Impact
IssuanceOfStockForCashEquityImpact
110033 USD
CY2021Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
21100 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1116358 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3986118 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
47684218 USD
us-gaap Net Income Loss
NetIncomeLoss
-10475831 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-0 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-570 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
371043 USD
us-gaap Net Income Loss
NetIncomeLoss
-9939513 USD
us-gaap Depreciation
Depreciation
9090 USD
us-gaap Depreciation
Depreciation
11129 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1809196 USD
us-gaap Share Based Compensation
ShareBasedCompensation
3124615 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
953778 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
176824 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-254291 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
419671 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-16607 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8432093 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8027875 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9142 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12762 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
18048 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
43323 USD
gnpx Payments To Acquire Research And Development Assets
PaymentsToAcquireResearchAndDevelopmentAssets
51315 USD
gnpx Payments To Acquire Research And Development Assets
PaymentsToAcquireResearchAndDevelopmentAssets
92219 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-78505 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-148304 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25434363 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
28300866 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25434363 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
28300866 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
16923765 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
20124687 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27319684 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2002492 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
44243449 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22127179 USD
us-gaap Interest Paid Net
InterestPaidNet
0 USD
us-gaap Interest Paid Net
InterestPaidNet
0 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2018Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
6.6841954 pure
CY2018Q1 gnpx Capital Stock Shares Authorized
CapitalStockSharesAuthorized
210000000
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2010 gnpx Proceeds From State Of Texas Emerging Technology Fund Award
ProceedsFromStateOfTexasEmergingTechnologyFundAward
2250000 USD
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Use of Estimates</i></span></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The preparation of our unaudited condensed financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p>
CY2021Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
43990330 USD
CY2020Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
27091596 USD
CY2021Q2 gnpx Research And Development Assets Current
ResearchAndDevelopmentAssetsCurrent
3062357 USD
CY2020Q4 gnpx Research And Development Assets Current
ResearchAndDevelopmentAssetsCurrent
3011042 USD
CY2010Q4 gnpx State Of Texas Emerging Technology Fund Award Amount
StateOfTexasEmergingTechnologyFundAwardAmount
4500000 USD
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
395176
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
435031 USD
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
10000
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
41750 USD
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1277743
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1320155 USD
CY2020 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5511599
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2537731 USD
CY2020 gnpx Stock Issued During Period Shares Exercise Of Cashless Warrants
StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants
199630
CY2020 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
51432
CY2020 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
154648 USD
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47522857
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q2 gnpx Nonvoting To Voting Common Stock Conversion Ratio
NonvotingToVotingCommonStockConversionRatio
1 pure
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7476056
CY2019Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.45
CY2020 gnpx Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
550000
CY2020 gnpx Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
2.41
CY2020 gnpx Class Of Warrant Or Right Cancelled During Period
ClassOfWarrantOrRightCancelledDuringPeriod
44528
CY2020 gnpx Class Of Warrant Or Right Cancelled During Period Exercise Price
ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice
0.50
CY2020 gnpx Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
5826781
CY2020 gnpx Class Of Warrant Or Right Exercised During Period Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
0.47
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2154747
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.37
gnpx Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
25000
gnpx Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
7.22
gnpx Class Of Warrant Or Right Cancelled During Period
ClassOfWarrantOrRightCancelledDuringPeriod
-0
gnpx Class Of Warrant Or Right Cancelled During Period Exercise Price
ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice
0
gnpx Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
-0
gnpx Class Of Warrant Or Right Exercised During Period Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
0
CY2021Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2179747
CY2021Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.40
CY2021Q2 gnpx Class Of Warrant Or Right Vested Or Expected To Vest
ClassOfWarrantOrRightVestedOrExpectedToVest
0
CY2021Q2 gnpx Class Of Warrant Or Right Vested Or Expected To Vest Weighted Average Exercise Price
ClassOfWarrantOrRightVestedOrExpectedToVestWeightedAverageExercisePrice
0
CY2021Q2 gnpx Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
1929747
CY2021Q2 gnpx Class Of Warrant Or Right Exercisable Exercise Price
ClassOfWarrantOrRightExercisableExercisePrice
4.64
CY2020 gnpx Stock Issued During Period Shares Warrants Issued
StockIssuedDuringPeriodSharesWarrantsIssued
5511599
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2537731 USD
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
315182
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7938521
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1499628
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
10000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
7.22
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
395176
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2466529
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
327640
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1277743
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M8D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y21D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5982923
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.66
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2466529
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.87
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1277743
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.03
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
327640
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
8.31
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6844069
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.81
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1499628
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.01
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
395176
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.10
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
10000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
7.22
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7938521
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.34
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
443535
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
2.99
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4820913
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.97

Files In Submission

Name View Source Status
0001437749-21-019892-index-headers.html Edgar Link pending
0001437749-21-019892-index.html Edgar Link pending
0001437749-21-019892.txt Edgar Link pending
0001437749-21-019892-xbrl.zip Edgar Link pending
ex_254209.htm Edgar Link pending
ex_254210.htm Edgar Link pending
ex_254211.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gnpx-20210630.xsd Edgar Link pending
gnpx-20210630_cal.xml Edgar Link unprocessable
gnpx-20210630_def.xml Edgar Link unprocessable
gnpx-20210630_lab.xml Edgar Link unprocessable
gnpx-20210630_pre.xml Edgar Link unprocessable
gnpx20210630_10q.htm Edgar Link pending
gnpx20210630_10q_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending